+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID05703971

Phase 12 Trial of Quaratusugene Ozeplasmid with Atezolizumab as Maintenance Therapy for Extensive Stage Small Cell Lung Cancer

Led by Genprex, Inc. · Updated on 2026-09-11

62

Participants Needed

17

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of quaratusugene ozeplasmid and atezolizumab as maintenance therapy for adults with Extensive Stage Small Cell Lung Cancer ES-SCLC who have not experienced tumor progression after initial treatment with carboplatin, etoposide, and atezolizumab. This open-label Phase 12 study aims to determine the right dose and assess safety and effectiveness of this combination therapy. The study is led by Genprex, Inc. and includes a dose selection phase followed by a safety and efficacy phase. In the dose selection phase Phase 1, patients received quaratusugene ozeplasmid intravenously every 21 days at increasing doses combined with atezolizumab given intravenously every 21 days to find the recommended dose for Phase 2. In Phase 2, patients receive the recommended dose of quaratusugene ozeplasmid with atezolizumab or with atezolizumab plus hyaluronidase-tqjs administered subcutaneously every 21 days. Treatment continues until the disease progresses or unacceptable side effects occur. Participants will have regular assessments including monitoring for side effects using standardized criteria, blood tests to check kidney, liver, and blood cell function, and cardiac evaluations. Researchers will measure outcomes such as the maximum tolerated dose, progression-free survival at 18 weeks, overall survival, and pharmacokinetics of the study drug. Participation lasts through the treatment period and follow-up evaluations to monitor safety and effectiveness, with the primary completion expected by December 2027.

CONDITIONS

Brief Title

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

Research Team

S

Sr Director, Clinical Operations

C

Chief Medical Officer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here